HLVX HilleVax Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: HLVX

Price (delayed)

$13.61

Market cap

$676.43M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.04

Enterprise value

$509.31M

Highlights
HLVX's EPS is up by 48% year-on-year but it is down by 33% since the previous quarter
HilleVax's net income has increased by 23% YoY but it has decreased by 15% QoQ
HLVX's quick ratio has dropped by 52% year-on-year and by 39% since the previous quarter
HLVX's debt is up by 41% year-on-year
Sector: Healthcare
Industry: Biotechnology
Peers: OMER OMGA

Key stats

What are the main financial stats of HLVX
Market
Shares outstanding
49.7M
Market cap
$676.43M
Enterprise value
$509.31M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.48
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$121.17M
EBITDA
-$119.02M
Free cash flow
-$97.53M
Per share
EPS
-$3.04
Free cash flow per share
-$2.4
Book value per share
$5.48
Revenue per share
$0
TBVPS
$8.48
Balance sheet
Total assets
$344.43M
Total liabilities
$78.91M
Debt
$51.19M
Equity
$265.53M
Working capital
$281.41M
Liquidity
Debt to equity
0.19
Current ratio
10.62
Quick ratio
10.43
Net debt/EBITDA
1.4
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-38.1%
Return on equity
-48.2%
Return on invested capital
-87.9%
Return on capital employed
-38.4%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

HLVX stock price

How has the HilleVax stock price performed over time
Intraday
-2.92%
1 week
6.41%
1 month
-8.16%
1 year
-2.16%
YTD
-15.2%
QTD
-18.16%

Financial performance

How have HilleVax's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$133.35M
Net income
-$123.57M
Gross margin
N/A
Net margin
N/A
HilleVax's operating income has shrunk by 105% YoY and by 15% QoQ
HilleVax's net income has increased by 23% YoY but it has decreased by 15% QoQ

Growth

What is HilleVax's growth rate over time

Valuation

What is HilleVax stock price valuation
P/E
N/A
P/B
2.48
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
HLVX's EPS is up by 48% year-on-year but it is down by 33% since the previous quarter
The equity has declined by 11% since the previous quarter
HLVX's price to book (P/B) is 4.6% less than its last 4 quarters average of 2.6

Efficiency

How efficient is HilleVax business performance
The ROIC has soared by 94% YoY and by 3.9% from the previous quarter
HilleVax's ROE has increased by 48% YoY but it has decreased by 15% from the previous quarter
The return on assets has increased by 35% year-on-year but it has declined by 12% since the previous quarter

Dividends

What is HLVX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for HLVX.

Financial health

How did HilleVax financials performed over time
The total liabilities has soared by 58% YoY and by 15% from the previous quarter
HLVX's quick ratio has dropped by 52% year-on-year and by 39% since the previous quarter
HLVX's debt is 81% smaller than its equity
HLVX's debt is up by 41% year-on-year
The debt to equity has grown by 36% year-on-year and by 12% since the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.